Trial Profile

Phase 1 Study To Assess the Safety and Tolerability of Human Embryonic Stem Cell-Derived Midbrain Dopamine Neuron Cell Therapy (MSK-DA01) For Advanced Parkinson's Disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bemdaneprocel (Primary)
Indications Parkinson's disease
Focus Adverse reactions
Acronyms exPDite
Sponsors BlueRock Therapeutics

Most Recent Events

07 Oct 2025 Results published in a BlueRock Therapeutics media release
07 Oct 2025 According to a BlueRock Therapeutics media release, positive 36-month data from expedite phase I clinical trial of bemdaneprocel for the treatment of Parkinson's disease, were presented on October 6 at the International Congress of Parkinson's Disease and Movement Disorders.
27 Sep 2024 Results presented in a BlueRock Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com